


N-BENZENE-SULFONYL-INDOLE AS TERMINATOR IN A BIOMIMETIC  
POLYENE CYCLIZATION : SYNTHESIS OF A PENTACYCLIC INDOLOSESQUITERPENE

Catherine Mirand, Michèle Döé de Maindreville, Dominique Cartier and Jean Lévy

UA/CNRS n°492, Université de Reims, Faculté de Pharmacie  
51 rue Cognacq-Jay, F 51096 Reims Cédex France

Summary. Epoxide 14 was cyclized with  $\text{BF}_3$  to the pentacyclic derivative 17, which was further elaborated to 19, a stereoisomer of the natural indolosesquiterpene polyveoline.


Polyveoline 3<sup>1</sup> (scheme 1), a representative of a series of indolosesquiterpenes<sup>2</sup>, might result in the plant from the linkage of a preformed drimane sesquiterpene with an indole<sup>2</sup>, or from the polyenic cyclization of an  $\omega$ -epoxido-farnesyl-indole. The second hypothesis brings up the question of indole acting as terminator in a polyene cyclization.



A preceding paper<sup>3</sup> described the synthesis and attempted cyclization of 3'- $\omega$ -epoxido-farnesyl-indoles. This study refers to the 2'-farnesyl-indole series, with regard to the possibly biogenetic sequence 1  $\rightarrow$  2  $\rightarrow$  3. However the *in vitro* feasibility of the sequence was evaluated starting with the more easily available E,E-farnesol instead of the Z-E-isomer required by the actual ring junctions of polyveoline.

The farnesyl chain was branched using Sundberg's 2-alkylation of 1-benzenesulfonyl indole<sup>4</sup>. E,E-farnesyl bromide thus gave 4<sup>5</sup> (70%) (scheme 2). The Van Tamelen regiospecific epoxidation<sup>6</sup> next needed protecting the labile indole nucleus with an otherwise lipophilic group; in a first route, the N-trifluoroacetyl indoline 7 was prepared from 4 through successive hydrolysis (1N ethanolic KOH, refl., 14 h.  $\rightarrow$  5, 90%), reduction ( $\text{NaBH}_3\text{CN}/\text{HClO}_4/\text{MeOH}$ , rt, 20 min.  $\rightarrow$  6, 75%) and acylation (TFAA, rt, 15 min.  $\rightarrow$  7, 100%). It was then elaborated *via* bromohydrin 8 to epoxide 9 (60% : i) NBS, 1.2 eq/DME/ $\text{H}_2\text{O}$  9:1, rt, 2 h. ; ii)  $\text{K}_2\text{CO}_3/\text{MeOH}$ , rt, 1 h.), which was N-protected ( $\text{NaBH}_4$ , 1 eq./MeOH, rt, 20 min.  $\rightarrow$  indoline 10, 80%). The final step involved reoxidation of the indole nucleus through a Rushig procedure<sup>3</sup> : i) NCS, 1.1 eq/ $\text{Et}_3\text{N}$ , 1.1 eq/ $\text{CH}_2\text{Cl}_2$ ,  $-10^\circ\text{C}$ , 5 min. ; ii) DBU. However C-3' suffered a very easy oxida-


tion in this series and the 3'-chloroindole 11 was the only isolated product (30%)<sup>7</sup>.



Scheme 2

This failure prompted to test sulphonamide 4 as a protected indole in the epoxidation process. Actually it reacted with NBS to yield the N-protected bromohydrin 12, which then gave the required epoxide 13 upon reaction with 1N ethanolic KOH (75°C, 7 h. : 11 → 13, 25%). Alternatively, treatment of the bromohydrin with K<sub>2</sub>CO<sub>3</sub>/MeOH (rt, 1 h.) yielded the N-protected epoxide 14 (95%).

Attempts of cyclization of epoxide 13 with BF<sub>3</sub> etherate in CH<sub>2</sub>Cl<sub>2</sub> led to a complex mixture from which only the tricyclic oxide 15 (10%) could be isolated and characterized with confidence<sup>8</sup> (scheme 3).



Scheme 3

An adverse unfolding of 13 was then suspected to originate from fixation of BF<sub>3</sub> on both oxygen and nitrogen atom, which designated the sulphonamide 14 as a more appropriate substrate. Gratifying enough, the sulphonamide group proved to lower the basicity of indole to such an extent that it did not prevent it from terminating the polyene cyclization : this time again BF<sub>3</sub> etherate gave a number of derivatives. Repeated tlc allowed isolation of the tricyclic oxide 16 (13%) and of a crystalline compound (13%, mp 265°C), which was ascribed the pentacyclic structure 17.

This compound,  $M^+$  477, had no olefinic proton or carbon and no indolic H-3'. Its four methyl groups were borne by quaternary carbons ( $^1\text{H}$  and  $^{13}\text{C}$  NMR). The eight other aliphatic carbons were three tertiary and five secondary ones. An equatorial OH group had resulted from the cyclization as indicated by a sharp singlet at 1.5 ppm, by a dd at 3.3 ppm ( $J=10.4$  and  $5.8\text{Hz}$ , H-3), and by the signal of C-3 at 79.0 ppm. Completion of the cyclization by the closure of a cyclopentene ring was supported by the base peak M-15 in the MS of 17 (cleavage of the benzylic 8,12-bond) and by homonuclear and heteronuclear NMR correlations : signals at 67.0 and 26.4 ppm were unequivocally attributed to C-9 and C-11, respectively, and the three protons on these carbons were seen as a 3-spin system at 2.10 (H-9), 2.83 and 2.99 (H-11) ppm ( $J=6, 12$  and  $15\text{Hz}$ ). These three protons did not exhibit any other short range coupling.

These results leave little doubt as to the structure of 17. Its configuration rests on its synthesis from E,E-farnesyl indole, on the chemical shifts of the methyl groups<sup>9,2</sup>, and on the coupling constants of H-3 and H-9<sup>10</sup>.

Finally, the sulphonamide 17 was N-deprotected to 18 (1N KOH/EtOH, 50%) and further reduced to indoline 19, mp  $210^\circ\text{C}$ ,  $M^+$  339 ( $\text{NaBH}_3\text{CN/TFA}$ , 65%), a stereoisomer of polyveoline. Reduction of the indole nucleus from the  $\alpha$ -face results in a clear anisotropic effect of the benzene ring on the C-12 methyl ( $\delta=0.65$  ppm).

The N-benzylsulfonyl group thus behaved as a highly efficient assistant in this synthesis, as it successively contributed to the 2'-alkylation of indole, to the regioselective epoxidation of the resulting 2'-farnesyl-indole, and to the termination of the biomimetic cyclization.

#### References and Notes

- 1) a) C.Riche, A.Chiaroni, G.Dubois, R.Hocquemiller, M.Leboeuf and A.Cavé, *Planta Medica*, 39, 206 (1980); b) R.Hocquemiller, G.Dubois, M.Leboeuf, A.Cavé, N.Kunesch, C.Riche and A.Chiaroni, *Tetrahedron Lett.*, 22, 5057 (1981).
- 2) P.G.Waterman in "Alkaloids", S.W.Pelletier, J.Wiley Ed., New-York, Vol.3, 91 (1985).
- 3) C.Mirand, M.Döé de Maindreville and J.Lévy, *Tetrahedron Lett.*, 26, 3985 (1985).
- 4) R.J.Sundberg and H.F.Russel, *J.Org.Chem.*, 38, 3324 (1973).
- 5) The NMR and mass spectra of all intermediates were fully consistent with the structures. Selected data : UV(MeOH,  $\lambda_{\text{max}}$  nm);  $^1\text{H}$  NMR(300MHz ;  $\text{CDCl}_3$ ) ;  $^{13}\text{C}$  NMR(75MHz,  $\text{CDCl}_3$  unless otherwise specified).  
43 :  $M^+$  337 ; UV 230,280,292 ;  $^1\text{H}$  NMR 1.27(s,3H), 1.29(s,3H), 1.64(s,3H), 1.68(s,3H), 2.7(t,1H, $J=6$ ), 3.47(d,2H, $J=7.5$ ), 5.17(t,1H, $J=7$ ), 5.38(t,1H, $J=7$ ), 6.22(s,1H), 6.8-7.6(m,4H), 8.05(brs,1H)

- 14 :  $M^+$  477 ; UV 215,250 ;  $^1H$  NMR 1.26(s,3H), 1.30(s,3H), 1.60(s,3H), 1.63(s,3H), 2.72(t,1H,J=6), 3.66(d,2H,J=7.5), 5.18(t,1H,J=7), 5.40(t,1H,J=7), 6.35(s,1H), 7.17-7.83(m,8H), 8.18(d,1H,J=8)
- 15 :  $M^+$  337 ;  $^1H$  NMR 1.02(s,3H), 1.06(s,3H), 1.32(s,3H), 1.72(s,3H), 3.50(d,2H,J=7.5), 3.72(d,1H,J=6), 5.40(t,1H,J=7), 6.22(s,1H), 7.0-7.6(m,4H), 7.87(s,1H) ;  $^{13}C$  NMR 16.2, 18.9, 23.4, 26.1(CI), 25.7, 26.1, 27.0, 39.0, 39.8(CII), 55.3, 86.0, 99.5, 110.3, 119.6, 119.7, 120.1, 120.9(CIII), 45.2, 86.7, 128.8, 135.8, 138.4, 138.5(CIV)
- 16 :  $M^+$  477 ;  $^1H$  NMR 1.04(s,3H), 1.08(s,3H), 1.35(s,3H), 1.60(s,3H), 3.68(d,2H,J=7.5), 3.74(d,1H,J=6), 5.40(t,1H,J=7), 6.35(s,1H), 7.15-7.85(m,8H), 8.18(d,1H,J=8)
- 17 :  $M^+$  477 ; UV 210, 255 ; IR(KBr) 3350 ;  $^1H$  NMR 0.87(s,3H), 1.01(s,3H), 1.08(s,3H), 1.10(s,3H), 1.50(s,1H), 2.10(dd,1H,J=12, 6), 2.27(dd,1H,J=8, 3), 2.83(dd,1H,J=15, 12), 2.99(dd,1H,J=15.0, 6), 3.30(dd,1H,J=10.4,5.8), 7.10-7.60(m,8H), 8.0(m,1H) ;  $^{13}C$  NMR 15.1, 16.6, 21.3, 28.0(CI), 19.0, 26.4, 27.1, 37.0, 38.5(CII), 56.1, 67.0, 79.0, 114.6, 118.7, 123.2, 123.3, 126.4, 129.2, 135.6(CIII), 36.9, 39.0, 43.3, 125.9, 136.0, 138.7, 139.2, 141.8(CIV)
- 18 :  $M^+$  337 ; UV 225,277,289 ;  $^1H$  NMR 0.87(s,3H), 1.00(s,3H), 1.10(s,3H), 1.13(s,3H), 2.21(dd,1H,J=12, 6), 2.38(dd,1H,J=8, 3), 2.56(dd,1H,J=15, 6), 2.65(dd,1H,J=15, 12), 3.27(dd,1H,J=10, 6), 6.90-7.50(m,4H), 7.85(brs,1H) ;  $^{13}C$  NMR ( $CD_3OD$ ) 15.8, 17.1, 22.4, 28.6(CI), 20.4, 24.6, 27.8, 39.6, 39.9(CII), 57.9, 69.7, 79.9, 112.5, 118.5, 119.6, 120.5(CIII), 38.1, 40.1, 44.4, 124.3, 129.4, 141.1, 142.8(CIV)
- 19 :  $M^+$  339 ; UV 208,245,295 ;  $^1H$  NMR 0.65(s,3H), 0.80(s,3H), 0.90(s,3H), 1.00(s,3H), 3.15(d,1H,J=10), 3.23(dd,1H,J=10, 6), 4.36(ddd,1H,J=10, 7.5, 6), 6.5-7.0(m,4H) ;  $^{13}C$  NMR ( $CD_3OD$ ) 15.2, 16.2, 16.6, 28.1(CI), 18.9, 27.1, 31.6, 38.8, 40.8(CII), 56.0, 61.4, 62.5, 63.0, 79.2, 109.3, 118.4, 125.0, 127.6(CIII), 36.7, 44.5, 61.4, 129.9, 152.2(CIV).
- 6) E.E. van Tâmelen and T.J.Curphey, Tetrahedron Lett., 121 (1962).
- 7) Chlorination of 13 (NCS,  $Et_3N$ ) was shown to give 11 (75%).
- 8) No significative improvement was gained by using less lipophilic solvents in the cyclization step or by acetylation of the reaction mixture.
- 9) E.Wenkert, G.V.Baddeley, I.R.Burfitt, L.N.Moreno, Org.Magnetic Resonance, 11, 337 (1978).
- 10) H-5 resonated in the 1 ppm area with the methyl groups so that its coupling constants could not be measured.

(Received in France 5 April 1987)